elements
-live
Search elements, keywords, and sectors
🔎
Elements
Subjects
Papers
Communities
Lab
Pricing
Log in
Sign up
Home
/
Subjects
/
Relapsing remitting
← Back to subjects
Current data, viewed at
Yearly
resolution.
Personal members see monthly resolution →
Keyword
keyword
Relapsing remitting
RIS
0.001
(Research Intensity Score)
Papers
42
Top papers
Dysregulation of the Kynurenine Pathway in Relapsing Remitting Multiple Sclerosis and Its Correlations With Progressive Neurodegeneration
2025 · 16 citations
Clinical Characteristics and Disability Progression of Early- and Late-Onset Multiple Sclerosis Compared to Adult-Onset Multiple Sclerosis
2020 · 109 citations
Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis
2018 · 215 citations
Longitudinal accumulation of glial activation measured by TSPO-PET predicts later brain atrophy in multiple sclerosis
2025 · 9 citations
Clinical and mechanistic effects of cladribine in relapsing multiple sclerosis: 2-year results from the MAGNIFY-MS Study
2025 · 9 citations
Effectiveness of Disease-Modifying Therapies in Patients With Late-Onset Relapsing-Remitting Multiple Sclerosis
2025 · 8 citations
Real-world effectiveness and safety of ofatumumab in relapsing-remitting multiple sclerosis: Insights from naïve and switch patients
2025 · 7 citations
Ocrelizumab dose selection for treatment of pediatric relapsing–remitting multiple sclerosis: results of the OPERETTA I study
2025 · 9 citations
Paramagnetic rim lesions are associated with choroid plexus inflammation and expansion over 5 years in people with multiple sclerosis
2025 · 6 citations
Newest papers
Long-term efficacy of cladribine tablets: Results from the MAGNIFY-MS Extension study
2026
Dysregulation of the Kynurenine Pathway in Relapsing Remitting Multiple Sclerosis and Its Correlations With Progressive Neurodegeneration
2025 · 16 citations
Longitudinal accumulation of glial activation measured by TSPO-PET predicts later brain atrophy in multiple sclerosis
2025 · 9 citations
Clinical and mechanistic effects of cladribine in relapsing multiple sclerosis: 2-year results from the MAGNIFY-MS Study
2025 · 9 citations
Effectiveness of Disease-Modifying Therapies in Patients With Late-Onset Relapsing-Remitting Multiple Sclerosis
2025 · 8 citations
Real-world effectiveness and safety of ofatumumab in relapsing-remitting multiple sclerosis: Insights from naïve and switch patients
2025 · 7 citations
Ocrelizumab dose selection for treatment of pediatric relapsing–remitting multiple sclerosis: results of the OPERETTA I study
2025 · 9 citations
Paramagnetic rim lesions are associated with choroid plexus inflammation and expansion over 5 years in people with multiple sclerosis
2025 · 6 citations
First-year treatment response predicts the following 5-year disease course in patients with relapsing-remitting multiple sclerosis
2025 · 7 citations
Browse all papers →
Relapsing remitting's history
Research intensity over time
Yearly
Personal members see monthly resolution →
Data temporarily unavailable — please try again shortly.
Close ✕
Relapsing remitting's papers
Ordered by current research-activity contribution.
Loading…
Close ✕
Read full text ↗
Share
Share on X
Share on Facebook
Share on LinkedIn
Copy link